Extracellular vesicle-based therapy for amyotrophic lateral sclerosis

Nadia Sadanandan, Jea-Young Lee, Svitlana Garbuzova-Davis

Abstract:
Amyotrophic lateral sclerosis (ALS) stands as a neurodegenerative disorder characterized by the rapid progression of motor neuron loss in the brain and spinal cord. Unfortunately, treatment options for ALS are limited, and therefore, novel therapies that prevent further motor neuron degeneration are of dire need. In ALS, the infiltration of pathological elements from the blood to the central nervous system (CNS) compartment that spur motor neuron damage may be prevented via restoration of the impaired blood-CNS-barrier. Transplantation of human bone marrow endothelial progenitor cells (hBM-EPCs) demonstrated therapeutic promise in a mouse model of ALS due to their capacity to mitigate the altered blood-CNS-barrier by restoring endothelial cell (EC) integrity. Remarkably, the hBM-EPCs can release angiogenic factors that endogenously ameliorate impaired ECs. In addition, these cells may produce extracellular vesicles (EVs) that carry a wide range of vesicular factors, which aid in alleviating EC damage. In an in vitro study, hBM-EPC-derived EVs were effectively uptaken by the mouse brain endothelial cells (mBECs) and cell damage was significantly attenuated. Interestingly, the incorporation of EVs into mBECs was inhibited via β1 integrin hindrance. This review explores preclinical studies of the therapeutic potential of hBM-EPC-derived EVs, for the repair of the damaged blood-CNS-barrier in ALS as a novel treatment approach.

Keywords:
Neurodegenerative disorder, ALS, blood-CNS-barrier, stem cell, extracellular vesicle, transplantation

Introduction
Previous research has demonstrated that extracellular vesicles (EVs) play a crucial role in regulating communication between cells in a variety of physiological and pathological circumstances and compose of microvesicles, apoptotic bodies, and exosomes.[1,2] Microvesicles are 50–1,000 nm in size, exosomes are 40–120 nm, and apoptotic bodies are 500–2,000 nm.[2,3] EVs are not only distinguished by constituent’s sizes, but also by inner contents and biogenesis pathways.[2,8] Importantly, EVs are largely involved in mediating cross-talk between cells by transporting a variety of biomolecules (e.g., proteins, lipids, peptides, mRNA, microRNA) among cells. As a result, EVs contribute to stem cell plasticity,[1,10] immune system responses,[11-14] and angiogenesis.[15,16] In addition, EVs may play a role in the transport of therapeutic factors from stem cells[17] that bear regenerative capacity, promote angiogenesis, attenuate inflammation, and inhibit apoptosis.[18]

Due to the capacity of nanovesicles to traverse the blood-brain barrier and their low tendency to evoke an immune response, nanoparticle-based therapies have arisen as potential deliverers of therapeutics for the treatment of neurodegenerative illnesses.[2,4,19] Notably, human bone marrow (hBM) mesenchymal stromal cells (MSC)-derived EVs demonstrated rehabilitative capacity in animal models of lung injury induced by either LPS[20] or ischemia-reperfusion,[21] as well as of kidney damage[22] and sepsis.[23] In myocardial ischemia/reperfusion injury mice,
exosomes derived from MSCs diminished infarct volume. Following treatment with MSC-isolated exosomes, healing of femur fracture in mice accelerated. In immunodeficient SCID mice, endothelial cell (EC) viability, proliferation, and angiogenesis were promoted by human endothelial progenitor cell (EPC)-derived microvesicle administration. Another study using SCID mice explored the efficacy of human pancreatic islet xenotransplantation in conjunction with microvesicles harvested from EPCs in ameliorating immune deficiency. Notably, this combined therapy enhanced angiogenesis and upregulated the production and release of insulin in treated mice. Thus, EVs may serve as effective transporters for the therapeutic delivery of various cargo proteins in the treatment of numerous diseases. Nonetheless, the mechanism underlying EV cargo delivery warrants further investigation. This review discusses the efficacy of EVs in treating amyotrophic lateral sclerosis (ALS), specifically EVs secreted by hBM-EPCs, and the mechanisms behind the therapeutic actions of these vesicles.

**Preclinical Studies Supporting Human Bone Marrow-Endothelial Progenitor Cells Therapy in Amyotrophic Lateral Sclerosis**

In contemplating the role EVs in hBM-EPC therapy, a brief introduction on the status of hBM-EPC therapy for ALS will provide a better appreciation of the scientific merit of EV contribution to regenerative medicine. In ALS studies of regenerative stem cell therapy targeting the impaired blood-central nervous system (CNS)-barrier, one of the pathogenic disease mechanisms, may serve as a potent therapeutic strategy for this aggressive neurodegenerative malady. When hBM-EPCs were delivered intravenously to symptomatic G93A SOD1 mutant mice (an ALS model), the blood-CNS-barrier was significantly restored potentially due to the replacement of damaged ECs with “healthy” transplanted cells. Barrier functionality in gray matter horns and white matter columns in the spinal cord, as well as in gray and white matter in the cerebral motor cortex/brainstem was substantially ameliorated following extensive hBM-EPC engraftment. This improvement of barrier structure and function in the SOD1 mutant mice was observed through a significant reduction in capillary permeability and bolstering of perivascular astrocyte end-feet function. Therefore, the manifestations of disease in these mice were greatly mitigated via blood-CNS-barrier restoration, resulting in augmented motor neuron viability in the spinal cord.

A subsequent *in vitro* study examined the mechanism underlying hBM-EPC-mediated blood-CNS-barrier repair. Cultured hBM-EPCs were observed in a normogenic environment at various time points. Notably, the cells demonstrated a steady secretion of VEGF-A and angiogenin-1, as well as structural changes in cytoskeletal F-actin filaments, and immunofluorescence of zona adherens 1 and occludin. Furthermore, these results indicate that hBM-EPCs may provide endogenous endothelium repair behind the rehabilitative capacity of these cells along with cell replacement of damaged ECs. In a similar investigation, human peripheral blood-derived EPCs promoted angiogenesis and renewal of impaired brain tissue injury via secretion of biomolecules. On account of hBM-EPCs’ capacity to replace damaged ECs and also bolster EC functionality, the efficacy of both of these reparative mechanisms in alleviating ALS-induced blood-CNS-barrier injury should be examined.

**The Therapeutic Potential of Human Bone Marrow-Endothelial Progenitor Cells-Derived Extracellular Vesicles in Amyotrophic Lateral Sclerosis**

Recently, the preclinical study has explored hBM-EPC-derived EVs as cell-free therapeutics for blood-CNS-barrier restoration in conditions mirroring ALS. An *in vitro* investigation found that hBM-EPC-derived EVs served as nanosized vesicles and after adding to culture media at concentration of 1 μg/ml, were effectively integrated into mouse brain endothelial cells (mBECs) and ameliorated ALS-induced injury of mBECs following exposure to plasma obtained from symptomatic ALS mice. The total protein content and size of the EVs were noted at specific culture time points during normogenic conditioning. Indeed, EVs are heterogeneous in size and content; however, these vesicles primarily consist of exosomes and microvesicles. Interestingly, the apoptotic bodies in EVs were noted upon vesicle isolation from the hBM-EPC cultures at 5 DIV. The appearance of these EV constituents may be explained by the natural variations in cellular nuclei and cytosol shapes that ensue with apoptosis. Of note, another *in vitro* study found morphological variations in hBM-EPCs, as the cells transformed from more rounded at 24 h to more elongated at 72 h.

The hBM-EPCs were subject to ALS plasma derived from symptomatic G93A SOD1 mice in culture. It has been shown that G93A SOD1 mutant mice during disease progression contain high levels of the unfavorable humoral factor, as well as heightened concentrations of pro-inflammatory type I cytokines and comparatively lower levels of anti-inflammatory type II cytokines. As exposure to ALS mouse plasma grew, cell death accompanied by morphological changes in hBM-EPCs was also increased. Notably, 97 cytokines in the blood plasma of G93A SOD1 mutant mice over the course of disease were delineated, and an upregulated
concentration of multiple cytokines correlated with increased mortality rate for mice.\[^{33}\] However, these biomolecules may not be effective as a prognostic tool due to disparities in levels of expression.\[^{33}\]

As a diagnostic marker for ALS, peripheral blood levels of particular cytokines may be useful.\[^{54}\] Plasma extracted from ALS patients exhibited upregulated concentrations of pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-\(\alpha\)), TNF receptor 1, interleukin-6 (IL-6), and IL-1\(\beta\).\[^{35-37}\] Through the trans-signaling pathway, humoral IL-6 may contribute to inflammation of ECs.\[^{38}\] Furthermore, the heightened levels of inflammatory cytokines associated with ALS, inducing neuroinflammation, may exacerbate transplanted cell viability in the bloodstream.\[^{17}\] In addition, ALS engenders deleterious humoral conditions with greater levels of injurious factors in the blood circulation, which may also negatively affect the functionality of endogenous ECs.\[^{17}\] Nevertheless, further investigation into the correlation between cytokine levels and their impact on ECs in ALS at various stages of the disease are warranted. An in vitro study utilizing mBECs examines this point. Upon 3% ALS mouse plasma treatment, cell survival of mBECs substantially decreased in vitro.\[^{17}\] However, adding 1 \(\mu\)g/ml of hBM-EPC-derived EVs to culture media greatly mitigated cell deterioration and warped morphology.\[^{17}\] Conversely, at an EV dose of 5 \(\mu\)g/ml, cell viability plummeted, indicating an EV level toxic to ECs. Furthermore, before clinical trials, extensive preclinical investigation is necessary to elucidate optimal dosage and timing of EV treatment.\[^{17}\]

MSCs have also risen as a potential source of EVs for cell-free therapeutics.\[^{2,5,8,21-25,39-42}\] Human BM-EPC-derived microvesicles have demonstrated therapeutic potency in animal models, specifically via the augmentation of angiogenesis.\[^{15,16}\] The microvesicles were incorporated in ECs and showed the ability to carry angiogenic factors to regions of brain injury.\[^{15}\] Importantly, the microvesicles mirrored the activity of the hBM-EPCs from which they were harvested and were critical for intercellular communication.\[^{8,43}\] Therefore, these EVs have been coined “nanosized extracellular organelles.”\[^{3}\]

### Potential Mechanisms Underlying Human Bone Marrow-Endothelial Progenitor Cells-Derived Extracellular Vesicles-Induced Neuroprotection in Amyotrophic Lateral Sclerosis

Preclinical studies have also explored the mechanisms behind EV uptake by cells, as well as mitigation of EC impairment spurred by ALS. Remarkably, hBM-EPCs secrete protein and lipid-based therapeutic factors that upregulate neuronal progenitor cell survival and differentiation \textit{in vitro}.\[^{44}\] Moreover, EVs harvested from hBM-EPCs may serve as potent carriers for therapeutic biomolecules in neurodegenerative disorders. The cellular and molecular links between neuroprotection to EC restoration remain an outstanding issue that requires further investigations. In mBEC culture, following the addition of hBM-EPC-derived EVs, the vesicles were found ubiquitously throughout the cytosol and cellular projections.\[^{17}\] Therefore, the therapeutic effects of these EVs may be due to their capacity to carry a wide range of biomolecules to various cell compartments, thereby aiding the preservation of cellular function.\[^{17}\] Nonetheless, a multi-omic investigation is warranted to delineate the types of biomolecules involved with the rehabilitative capacity of these EVs.\[^{17}\] In general, EVs vary significantly in structure, content, and biological mechanisms.\[^{2,45,46}\]

Notably, the following biomarkers have been found on the surface of exosomes: CD9, CD63, CD81, tetraspanins, and flotillin.\[^{47-50}\] With respect to microvesicles, integrins, selectins, and CD40 have been identified.\[^{16,51}\] Finally, annexin V, C2b, and thrombospondin have been delineated in apoptotic bodies.\[^{52-54}\] To more effectively distinguish EV subtypes, a ratio comparing the number of a particular biomarker with the others in the vesicles should be determined.\[^{17}\] Additionally, proteomic studies and analysis of RNA in EVs are key factors to delineate the molecular cargo of EVs and may aid in elucidating the EV mechanisms in ALS.\[^{17,54-57}\] Since EVs are enclosed in a heterogeneous phospholipid bilayer, investigation into how components of the membrane factor into EV structure, function, and stability is warranted.\[^{17}\] Regarding hBM-EPC-derived EVs specifically, delineating the composition of the lipid membrane may provide a molecular understanding of cellular fusion and fission for these vesicles.\[^{58}\] Moreover, in-depth investigations that aim to identify the protein and lipid composition of EVs may serve as a robust area of future research.\[^{59}\]

In addition to further elucidating the molecular heterogeneity of EVs isolated from hBM-EPCs, the mechanisms behind the incorporation of these vesicles into cells must be more extensively evaluated. Indeed, EVs may be uptaken by cells via membrane fusion, endocytosis, phagocytosis, and macropinocytosis.\[^{3}\] The particular pathways that drive EV incorporation are influenced by the membrane composition of the target cell and the vesicle, indicating the importance of identifying the proteins and/or glycoproteins involved in EV internalization.\[^{9}\] While EVs can be internalized into target cells via endolysosomal mechanisms or budding, endocytosis seems to be the most prominent pathway.\[^{5,58}\] Nevertheless, it is also important to assess
the fusion mechanism where the EV lipid membrane fuses directly with the membrane of target cells.[17,60] Future studies should investigate the mechanisms of EV uptake into target cells despite hindering or blocking by ligands or receptor-mediated incorporation.[2,5,12] Notably, microvesicle uptake by human EPCs was attenuated via the inhibition of α4 integrin and β1 integrin (CD29).[16] In vitro, preconditioning hBM-EPC-derived EVs with anti-CD29 inhibiting antibodies resulted in reduced uptake of EVs by mBECs.[17] Consequently, cell death was significantly exacerbated following exposure to 3% ALS mouse plasma compared to the effect of EV treatment.[17] Moreover, cell adhesion molecules may play a critical role in the uptake of EVs by receiving cells.[17]

**Conclusion**

In summary, EVs isolated from hBM-EPCs demonstrate potential therapeutic promise in ALS. Animal models of ALS showed substantial EC damage, leading to impairment of blood-CNS-barrier integrity. The effects of hBM-EPC-derived EVs culminated in ameliorated EC deterioration in vitro [Figure 1], most likely due to EV uptake into ECs and the release of therapeutic factors from the vesicles. This effect likely results from hBM-EPC transplantation. Nonetheless, the specific biomolecules secreted by these EVs have not been fully illuminated. Additionally, the safety and efficacy of these vesicles need to be investigated in vivo to further elucidate the therapeutic potency of hBM-EPC-derived EVs in ALS. This review paper is limited to the potential contribution of EVs derived from hBM-EPCs in the observed functional recovery in ALS following hBM-EPC transplantation. Other mechanisms of action, including but not limited to hBM-EPC differentiation and integration into the host brain tissue, equally warrant consideration in advancing hBM-EPC transplantation for ALS.

**Acknowledgment**

SGD is supported by the NIH, NINDS (1R01NS090962) grant. The figure was created using Adobe Photoshop.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Bakshandeh B, Kamaledin MA, Al-Shah K. A comprehensive review on exosomes and microvesicles as epigenetic factors. Curr Stem Cell Res Ther 2017;12:31-6.
2. El Andaloussi S, Mager I, Breakefield XO, Wood MJ. Extracellular vesicles: Biology and emerging therapeutic opportunities. Nat Rev Drug Discov 2013;12:547-57.
3. Gho YS, Lee C. Emergent properties of extracellular vesicles: A holistic approach to decode the complexity of intercellular communication networks. Mol Biosyst 2017;13:1291-6.
4. Iraci N, Leonardo T, Gessler F, Vega B, Pluchino S. Focus on extracellular vesicles: Physiological role and signalling properties of extracellular membrane vesicles. Int J Mol Sci 2016;17:171.
5. Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles 2014;4.
6. Tetta C, Ghigo E, Silengo L, Deregibus MC, Camussi G. Extracellular vesicles as an emerging mechanism of cell-to-cell communication. Endocrine 2013;44:11-9.
7. Yoon YJ, Kim OY, Gho YS. Extracellular vesicles as emerging intercellular communicasomes. BMB Rep 2014;47:531-9.
8. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 2014;30:255-89.
9. Gould SJ, Raposo G. As we wait: Coping with an imperfect nomenclature for extracellular vesicles. J Extracell Vesicles 2013;2.
10. Lee Y, El Andaloussi S, Wood MJ. Exosomes and microvesicles: Extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet 2012;21:R125-34.
11. Bobrie A, Colombo M, Raposo G, Théry C. Exosome secretion: Molecular mechanisms and roles in immune responses. Traffic 2011;12:1659-68.
12. Chaput N, Théry C. Exosomes: immune properties and potential clinical implementations. Semin Immunopathol 2011;33:419-40.
13. Robbins FD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol 2014;14:195-208.
14. Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009;9:581-93.
15. Cantaluppi V, Biancone L, Figliolini F, Beltramo S, Medica D, Deregibus MC, et al. Microvesicles derived from endothelial progenitor cells enhance neangiogenesis of human pancreatic islets. Cell Transplant 2012;21:1305-20.
16. Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, et al. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 2007;110:2440-8.
17. Garbuzova-Davis S, Willing AE, Ehrhart J, Wang L, Sanberg PR, Borlongan CV. Cell-free extracellular vesicles derived from human bone marrow endothelial progenitor cells as potential therapeutics for microvascular endothelium restoration in ALS. Neuromolecular Med 2020;22:503-16.
18. Suárez-Meade P, Carvajal HG, Yasuhara T, Tajiri N, Date I, Borlongan CV. Regenerative medicine for central nervous system disorders: Role of therapeutic molecules in stem cell therapy. Brain Circulation - Volume 7, Issue 1, January-March 2021
Circ 2015;1:125-32.

19. Das CK, Jena BC, Banerjee I, Das S, Parekh A, Bhutia SK, et al. Exosome as a novel shuttle for delivery of therapeutics across biological barriers. Mol Pharm 2019;16:24-40.

20. Morrison TJ, Jackson MV, Cunningham EK, Kissenpfennig A, McAuley DF, O’Kane CM, et al. Mesenchymal stem cell modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer. Am J Respir Crit Care Med 2017;196:1275-86.

21. Stone ML, Zhao Y, Robert Smith J, Weiss ML, Kron IL, Laubach VE, et al. Mesenchymal stem cell-derived extracellular vesicles attenuate lung ischemia-reperfusion injury and enhance reconditioning of donor lungs after circulatory death. Respir Res 2017;18:212.

22. Aghajani Nargesi A, Lerman LO, Eirin A. Mesenchymal stem cell-derived extracellular vesicles for kidney repair: Current status and looming challenges. Stem Cell Res Ther 2017;8:273.

23. Zheng G, Huang R, Qiu G, Ge M, Wang J, Shu Q, et al. Mesenchymal stem cell-derived extracellular vesicles: Regenerative and immunomodulatory effects and potential applications in sepsis. Cell Tissue Res 2018;374:1-5.

24. Lai RC, Arslan F, Lee MM, Sze NS, Choo AK, Chen TS, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res 2010;4:214-22.

25. Furuta T, Miyaki S, Ishitobi H, Ogura T, Kato Y, Kamei N, et al. Mesenchymal stem cell-derived exosomes promote fracture healing in a mouse model. Stem Cells Transl Med 2016;5:1620-30.

26. Eve DJ, Steiner G, Mahendraresah A, Sanberg PR, Kurien C, Thomson A, et al. Reduction of microhemorrhages in the spinal cord of symptomatic ALS mice after intravenous human bone marrow stem cell transplantation accompanies repair of the blood-spinal cord barrier. Oncotarget 2018;9:10621-34.

27. Garbuzova-Davis S, Kurien C, Thomson A, Falco D, Ahmad S, Staffetti J, et al. Endothelial and astrocytic support by human bone marrow stem cell grafts in symptomatic ALS mice towards blood-spinal cord barrier repair. Sci Rep 2017;7:8844.

28. Garbuzova-Davis S, Haller E, Navarro S, Besong TE, Boccio KJ, Hailu S, et al. Transplantation of human bone marrow stem cells into ALS mice enhances structural and functional blood-spinal cord barrier repair. Exp Neurol 2018;310:33-47.

29. Garbuzova-Davis S, Kurien C, Haller E, Eve DJ, Navarro S, Steiner G, et al. Human bone marrow endothelial progenitor cell transplantation into symptomatic ALS mice delays disease progression and increases motor neuron survival by repairing blood-spinal cord barrier. Sci Rep 2019;9:5280.

30. Garbuzova-Davis S, Ehrhart J, Mustafa H, Llaugut A, Boccio KJ, Sanberg PR, et al. Phenotypic characteristics of human bone marrow-derived endothelial progenitor cells in vitro support cell effectiveness for repair of the blood-spinal cord barrier in ALS. Brain Res 2019;1724:146428.

31. Urbich C, Aicher A, Heesschen C, Dembach E, Hofmann WK, Zeiher AM, et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005;39:733-42.

32. Jeyachandran A, Mertens B, McKissick EA, Mitchell CS. Type I Vs. Type II cytokine levels as a function of SOD1 G93A mouse amyotrophic lateral sclerosis disease progression. Front Cell Neurosci 2015;9:462.

33. Moreno-Martinez L, la Torre M, Toierson JM, Zaragoza P, García-Redondo A, Calvo AC, et al. Circulating cytokines could not be good prognostic biomarkers in a mouse model of amyotrophic lateral sclerosis. Front Immunol 2019;10:801.

34. Moreno-Martinez L, Calvo AC, Muñoz MJ, Osta R. Are circulating cytokines reliable biomarkers for amyotrophic lateral sclerosis? Int J Mol Sci 2019;20:2759.

35. Ehrhart J, Smith AJ, Kuzmin-Nichols N, Zesiewicz TA, Jahan I, Shytle RD, et al. Humoral factors in ALS patients during disease progression. J Neuroinflammation 2015;12:127.

36. Hu Y, Cao C, Qiu XY, Yu Y, Yuan J, Zhao Y, et al. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: A meta-analysis study. Sci Rep 2017;7:9094.

37. Lam L, Chin L, Halder RC, Sagong B, Famenini S, Sayre J, et al. Epigenetic changes in T-cell and monocyte signatures and production of neurotoxic cytokines in ALS patients. FASEB J 2016;30:3461-73.

38. Garbuzova-Davis S, Ehrhart J, Sanberg PR, Borlongan CV. Potential role of humoral IL-6 cytokine in mediating pro-inflammatory endothelial cell response in amyotrophic lateral sclerosis. Int J Mol Sci 2018;19:423.

39. Dabrowska S, Andrzejewska A, Lukomska B, Janowski M. Neuroinflammation as a target for treatment of stroke using mesenchymal stem cells and extracellular vesicles. J Neuroinflammation 2019;16:178.

40. Dabrowska S, Andrzejewska A, Strzemecki D, Muraca M, Janowski M, Lukomska B. Human bone marrow mesenchymal stem cell-derived extracellular vesicles attenuate neuroinflammation evoked by focal brain injury in rats. J Neuroinflammation 2019;16:216.

41. Qiu G, Zheng G, Ge M, Wang J, Huang R, Shu Q, et al. Mesenchymal stem cell-derived extracellular vesicles affect disease outcomes via transfer of microRNAs. Stem Cell Res Ther 2018;9:320.

42. Shojaati G, Khandaker I, Funderburgh ML, Mann MM, Basu R, Stolz DB, et al. Mesenchymal stem cells reduce corneal fibrosis and inflammation via extracellular vesicle-mediated delivery of miRNA. Stem Cells Transl Med 2019;8:1192-201.

43. Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancole L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 2010;78:838-48.

44. Sadanandan N, Di Santo S, Widmer HR. Another win for endothelial progenitor cells: Endothelial progenitor cell-derived conditioned medium promotes proliferation and exerts neuroprotection in cultured neuronal progenitor cells. Brain Circ 2019;5:106-11.

45. Akers JC, Gonda D, Kim R, Carter BS, Chen CC. Biogenesis of extracellular vesicles (EV): Exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol 2013;113:1-1.

46. György B, Szabó TG, Pásztói M, Pál Z, Misják P, Aradi B, et al. Exosomes/microvesicles and inflammation via extracellular vesicle-mediated delivery of miRNA. J Neuroinflammation 2019;16:1.

47. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science 2020;367:eaau9977.

48. Kowal J, Arras G, Colombo M, Jouve M, Morath JP, Primidal-Bengson B, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci U S A 2016;113:E968-77.

49. Rana S, Zöller M. Exosome target cell selection and the importance of exosomal tetraspanins: A hypothesis. Biochem Soc Trans 2011;39:559-62.

50. Raposo G, Stoorvogel W. Extracellular vesicles: Exosomes, microvesicles, and friends. J Cell Biol 2013;200:373-83.

51. Cuccu E, Racchetti G, Meldolesi J. Shedding microvesicles: Artefacts no more. Trends Cell Biol 2009;19:43-51.

52. Igami K, Uchiyumi T, Ueda S, Kamioka K, Setoyama D, Gotoh K, et al. Epigenetic changes in T-cell and monocyte signatures and looming challenges. Stem Cell Res Ther 2017;8:273.

53. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V-avidity assay: A review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998;31:1-9.

54. Choi DS, Kim DK, Kim YK, Gho YS. Proteomics of extracellular vesicles: Exosomes and ectosomes. Mass Spectrom Rev
Sadanandan, et al.: Stem cells and ALS

2015;34:474-90.

55. Hill AF, Pegtel DM, Lambertz U, Leonardi T, O’Driscoll L, Pluchino S, et al. ISEV position paper: Extracellular vesicle RNA analysis and bioinformatics. J Extracell Vesicles 2013;2.

56. Kim KM, Abdelmohsen K, Mustapic M, Kapogiannis D, Gorospe M. RNA in extracellular vesicles. Wiley Interdiscip Rev RNA 2017;8.

57. Mateescu B, Kowal EJ, van Balkom BW, Bartel S, Bhattacharyya SN, Buzás EI, et al. Obstacles and opportunities in the functional analysis of extracellular vesicle RNA – An ISEV position paper. J Extracell Vesicles 2017;6:1286095.

58. Chernomordik LV, Kozlov MM. Protein-lipid interplay in fusion and fission of biological membranes. Annu Rev Biochem 2003;72:175-207.

59. Osteikoetxea X, Balogh A, Szabó-Taylor K, Németh A, Szabó TG, Pálóczy K, et al. Improved characterization of EV preparations based on protein to lipid ratio and lipid properties. PloS One 2015;10:e0121184.

60. Subra C, Laulagnier K, Perret B, Record M. Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies. Biochimie 2007;89:205-12.